卵巢癌抗独特型抗体诱导特异性迟发过敏反应的实验研究  

The induction of specific immunity to humanovarian carcinoma cells hy anti-idiotypicantibodies

作　　者：吕文英[1] 钱和年[1] 李文锦[1] 

机构地区：[1]北京医科大学人民医院妇科肿瘤研究室

出　　处：《中华妇产科杂志》1994年第1期27-29,共3页Chinese Journal of Obstetrics and Gynecology

摘　　要：本研究应用卵巢癌抗原内影像型单克隆抗独特型抗体６Ｂ＿（１１）、和１Ｈ＿（１２）代替肿瘤抗原，诱导同系小鼠产生卵巢癌特异性细胞免疫反应——迟发性过敏反应（ＤＴＨ），从而证明了６Ｂ＿（１１）、和１Ｈ＿（１２）具有抗原模狐作用。经过６Ｂ＿（１１），或１Ｈ＿（１２）免疫的小鼠，用卵巢癌细胞系ＳＫＯＶ＿３进行脚掌注射攻击。而后，测量脚掌水肿厚度作为ＤＴＨ反应强度。６Ｂ＿（１１）、诱导的ＤＴＨ平均水肿厚度为０．９３ｍｍ，卵巢癌组织抗原ＯＣ＿（１６６－９）诱导的阳性对照组平均为１．１１ｍｍ，二者之间差异无显著性（Ｐ＞０．０５）；１Ｈ＿（１２）诱导的ＤＴＨ平均水肿厚度０．８２ｍｍ，明显低于阳性对照组（Ｐ＜０．０５）。免疫鼠对无关靶细胞（胃癌细胞）攻击呈阴性反应，证明６Ｂ＿（１１）和１Ｈ＿（１２）诱导的ＤＴＨ反应有明显特异性。观察病理切片可见，６Ｂ＿（１１）诱导的病变内可见大量炎细胞，呈弥漫性浸润，而１Ｈ＿（１２）诱导的炎性病灶呈条索状，局限于正常组织之间，二者形成明显对照。根据实验结果推测，６Ｂ＿（１１）、和１Ｈ＿（１２）在诱导特异性细胞免疫反应方面可能存在实质性差异。若用作肿瘤疫苗，６Ｂ＿（１１）可能比１Ｈ＿（１２）更有?onoclonal anti-idiotypic antibodies, 6B_(11) and H_(12), were employed instead of the tumor antigen toinduce a specific cellular immunity to ovariancarcinoma cell line SKOV_3. 6B_(11) and IH_(12) carryingthe internal image of ovarian carcinoma antigen.BALB / c mice were immunized with 6B_(11) or 1H_(12)and then the mouse foot pad was attacked by the in-petion of target cell SKOVs to stimulate a specific de-layedtype hypersensitivity (DTH). The resultsshowed that 6B_(11) induced a severe foot pad swelling(Mean thickness 0.93mm) as seen in the positive con-trol (P> 0.05) induced by ovarian carcinoma antigen,the 1H_(12) induced swelling was significantly lower thanthe positive control (P<0.05). Both 6B_(11), and1H_(12) expressed the effective responses only to SKOV_3,but not to the unrelated target cells. Pathological ex-amations found that there was marked infiltration ofinflammatory cells in foot pad of mice primed by6B_(11), while by 1H_(12), only induced a narrow pathologi-cal changes. These observations indicated that therewould be some essential differences between 6B_(11) and1H_(12) in the behavior of inducing the specific DTH toSKOK_3. And as an idiotypic vaccine, 6B_(11) would bemore powerful against ovarian carcinoma.

关 键 词：抗独特型 抗体 卵巢肿瘤 癌 

分 类 号：R737.310.3[医药卫生—肿瘤]